Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company ...

Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for.

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

GEM-X technology was introduced ... Macroeconomic uncertainties could impact spending in academia and biopharma. 10x Genomics delivered strong Q4 2023 results with substantial contributions ...

Biotech company 10x Genomics (NASDAQ:TXG ... and sequencing companies within the life sciences industry provide the technology for increasingly personalized medicine, drug discovery, and disease ...

(AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 ... Advertisement Article continues below this ad The life science technology company posted revenue of $165 million in the period, ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will ...

Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into a scheduled two-week trial, according to a Thursday filing in Delaware ...